Figure 2 shows a clear trend towards an increase in carboplatin clearance across consecutive cycles of treatment in six patients aged between 3 weeks and 5 months of age, where data were available from between 3 and 6 treatment cycles.
← all excerpts
Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom.
1
—
—